Fusion Antibodies PLC Exercise of share options and total voting rights (4932V)
December 14 2021 - 1:59AM
UK Regulatory
TIDMFAB
RNS Number : 4932V
Fusion Antibodies PLC
14 December 2021
14 December 2021
Fusion Antibodies plc
("Fusion" or the "Company")
Exercise of share options and total voting rights
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical
antibody discovery, engineering and supply for both therapeutic
drug and diagnostic applications , announces an exercise of share
options in the Company ("Ordinary Shares") by Richard Buick, Chief
Scientific Officer of the Company.
On 13 December 2021, Richard Buick exercised 20,000 share
options . These share options were granted pursuant to the
Company's EMI Employee Share Option Scheme with an exercise price
of 54.5 pence per share. The new Ordinary Shares issued pursuant to
this exercise will be admitted to trading on AIM pursuant to the
Block Admission announced by the Company on 27 September 2021 . The
notification below, made in accordance with the requirements of the
UK Market Abuse Regulation, provides further detail.
Following the above exercise of 20,000 share options, Richard
Buick holds 631,250 Ordinary Shares, representing approximately
2.43 per cent. of the Company's enlarged issued share capital.
Following the exercise of share options , the total number of
Ordinary Shares in issue is now 25,938,280. The Company does not
currently hold any Ordinary Shares in treasury. Therefore, the
total number of voting rights in the Company is 25,938,280, which
may be used by shareholders as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change to their interest in the Company under the
FCA's Disclosure Guidance and Transparency Rules.
The following notification, made in accordance with the
requirements of the UK Market Abuse Regulation, gives further
details.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Richard Buick
--------------------------- ----------------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------
a) Position/status Director - Chief Scientific Officer
--------------------------- ----------------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------- ----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name Fusion Antibodies plc
--------------------------- ----------------------------------------------
b) LEI 213800KBAYRC9VOQ9V39
--------------------------- ----------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------------
a) Description of the Ordinary shares of 4p each in Fusion
financial instrument, Antibodies plc
type of instrument Identification code (ISIN) for Fusion
Identification code Antibodies plc ordinary shares: GB00BDQZGK16
--------------------------- ----------------------------------------------
b) Nature of the transaction Exercise of share options
--------------------------- ----------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
GBP0.545 20,000
----------
--------------------------- ----------------------------------------------
d) Aggregated information
--------------------------- ----------------------------------------------
- Aggregated volume 20,000
-------------------------------- ----------------------------------------------
- Price GBP0.545
-------------------------------- ----------------------------------------------
e) Date of the transaction 13 December 2021
--------------------------- ----------------------------------------------
f) Place of the transaction Outside a trading venue
--------------------------- ----------------------------------------------
Enquiries:
Fusion Antibodies plc www.fusionantibodies.com
Richard Jones, Chief Executive Officer Via Walbrook PR
James Fair, Chief Financial Officer
Allenby Capital Limited Tel: +44 (0)20 3328 5656
James Reeve / Vivek Bhardwaj (Corporate
Finance)
Tony Quirke (Sales and Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741 001
Paul McManus Mob: +44 (0)7980 541 893
About Fusion Antibodies plc
Fusion is a Belfast-based Collaborative Research Organisation
("CRO") company, listed on AIM, providing a range of antibody
engineering services for the development of antibodies for both
therapeutic drug and diagnostic applications.
Fusion provides a broad range of services in antibody
generation, development, characterisation, optimisation, and
small-scale production. These services include antigen expression,
purification and sequencing, antibody humanisation using Fusion's
proprietary CDRx(TM) platform and cell line development, producing
antibody generating stable cell lines optimised for use downstream
by the customer to produce material for clinical trials. Since
2012, the Company has successfully sequenced and expressed over 250
antibodies and successfully completed over 200 humanisation
projects for its international customer base, which has included
eight of the top 10 global pharmaceutical companies by revenue.
At every stage, our client's vision is central to how we work in
combining the latest technological advances with cutting edge
science. In this work our world-class humanization and antibody
optimization platforms harness the power of natural somatic
hypermutation (SHM) to ensure the best molecule goes to the clinic.
Fusion Antibodies' growth strategy is based on enabling Pharma and
Biotech companies get to the clinic more effectively, using
molecules with optimized therapeutic profile and enhanced potential
for successful development and approval and, ultimately, on
speeding up the drug discovery and development process. Fusion's
use of SHM to create a fully human antibody library to capture the
human antibody repertoire will address a continuing market need in
antibody discovery,
Fusion Antibodies' emphasis on antibody therapeutics is based on
the size and growth rate in the sector, with the market valued at
$135.4 billion in 2018 and forecast to surpass $300 billion by
2025, a CAGR of 14.26%. As of May 2021, there were 100 approved
antibody therapies on the market and more than 570 antibody
therapies in clinical development.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRBLBDDCUBDGBX
(END) Dow Jones Newswires
December 14, 2021 01:59 ET (06:59 GMT)
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From Apr 2023 to Apr 2024